This is a preview of subscription content, log in via an institution to check access.
Notes
NICE = National Institute for Health and Care Excellence
see Reactions 1457 p2; 803088845
including the Medicines for Women's Health Expert Advisory Group, and the Paediatric Medicines Expert Advisory Group.
Reference
Medicines and Healthcare products Regulatory Agency (UK). Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy. Drug Safety Update 12: 6-7, No. 10, May 2019. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/802701/May-2019-PDF-DSU.pdf
Rights and permissions
About this article
Cite this article
Magnesium sulfate: neonatal skeletal AEs with in utero exposure. Reactions Weekly 1755, 3 (2019). https://doi.org/10.1007/s40278-019-62557-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-62557-8